Ramucirumab efficacy in first-line gastric and esophageal cancer treatment

Upper gastrointestinal cancers are highly lethal malignant diseases. Taken together gastric and esophageal (GE) cancers as a unique entity, both are estimated to be the third most incident and the second most lethal malignancies in both sexes worldwide. Despite the fact that GE cancer presents with a lower incidence in non-Asian countries with respect to Asian ones, its mortality is truly high in Occidental patients (29.3% survivors at 5 years) (1).